Spotlight on Pulmonary/Respiratory Medicine

Credits: 0.50 CME / MOC / CNE / CPE
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment
Michael G. Ison, MD, MS
RMEI Medical Education, LLC

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment

Start

Activity Details

Free CME/MOC/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Released: October 18, 2021
Expires: October 17, 2022
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Christopher J. Coyne, MD, MPH
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA


Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Released: October 18, 2021
Expires: October 17, 2022
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Christopher J. Coyne, MD, MPH
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA


Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pulmonary/Respiratory Medicine Presentations

0.50 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza in High-Risk Patients: Aching for Optimal Treatment

Start

Activity Details

Free CME/MOC/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Released: October 18, 2021
Expires: October 17, 2022
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Christopher J. Coyne, MD, MPH
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA


Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ANCC contact hour(s)
0.5 ACPE contact hour(s)
0.5 ABIM MOC point(s)
Released: October 18, 2021
Expires: October 17, 2022
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Christopher J. Coyne, MD, MPH
Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA


Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Christopher J. Coyne, MD, MPH, has a financial relationship with Gilead Pharmaceuticals (Other: Infectious disease screening program).

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-004-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Start

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); GlaxoSmithKline (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.75 CME
Integrity Continuing Education, Inc.
Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Virtual “Escape Rheum”: A Case-Based Guide to Diagnosis and Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 1, 2021
Expires: October 1, 2022
45 minutes to complete

Accredited By

Target Audience

This educational activity has been designed to meet the needs of rheumatology health care providers, including doctors, nurse practitioners, physician assistants, and other healthcare providers involved in the management of patients with CTD-PAH.

Learning Objectives

  • Recognize that patients with CTD are at increased risk for developing PAH.
  • Discuss the best practices for screening, diagnosis, classification, functional capacity classification, and utilization of echocardiography, and right heart catheterization (RHC) in CTD-PAH.
  • Review the clinical trial data, safety, efficacy, and side effect profiles of existing therapeutics for the management of PAH in the treatment of CTD-PAH based on evidence-based medicine and expert consensus.
  • Promote collaboration and care coordination across the multidisciplinary care team to optimize treatment in patients with CTD-PAH.
  • Identify communication strategies for promoting disease-understanding and shared decision-making among patients and caregivers to encourage them to take an active role in the disease management process.

Activity Description

Simulation Activity

Statement of Educational Need

Patients with rheumatic diseases are at higher risk of pulmonary arterial hypertension (PAH) secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This activity will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH. This educational activity will review the epidemiology, pathophysiology, and diagnostic strategies of PAH in patients with connective tissue diseases (CTD). Additionally, faculty will discuss which PAH therapies are beneficial for patients with CTD-PAH and the importance of a multidisciplinary team in managing these patients.

During this interactive online activity, learners listen to a brief lecture given by national faculty experts on diagnosis, staging, and treatment of patients with CTD-PAH. Learners will then enter an online escape room where they will be presented with a patient that they will work to diagnose and treat by answering clinical content questions to earn clues and lab results regarding their patient. Once they have treated the patient to the standard of care, the patient will be sent home with appropriate patient education and referrals to supportive care.

Faculty

Flavia Castelino, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Victor Tapson, MD
Professor of Medicine
Department of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Flavia Castelino, MD
No real or apparent conflicts of interest to disclose.

Victor Tapson, MD
Advisory Board: Actelion, Bayer, Johnson & Johnson, United Therapeutics
Research funding to institution: Actelion, Johnson & Johnson, United Therapeutics
Study Steering Committee: Bayer

The Integrity Continuing Education planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of October 1, 2021 through October 1, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Statement of Commercial Support

This program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson.

Disclaimer Statement

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

1.00 CME
Vindico Medical Education
The Changing Landscape of Immune-Based Therapies for COVID-19

The Changing Landscape of Immune-Based Therapies for COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
Vindico Medical Education
SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition

SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
  • Review treatment options based on clinical evidence and expert guidelines.
  • Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim


Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 31, 2021
Expires: August 30, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
  • Review treatment options based on clinical evidence and expert guidelines.
  • Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.

Activity Description

In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.

Statement of Educational Need

Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.

Agenda

Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty

Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland

Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty

Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland

Activity Chair

Elizabeth R. Volkmann, MD, MS
Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI

Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim


Kristin B. Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Compliance

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME / MOC
RMEI Medical Education, LLC
Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Overcoming Hurdles to Optimal Care for Patients with NTM-LD

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
Released: August 17, 2021
Expires: August 16, 2022
30 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current data, guidelines, and best practices when managing individuals with nontuberculous mycobacterial lung disease (NTM-LD)
  • Apply strategies to maintain adherence and address treatment-related adverse effects in patients with NTM-LD

Activity Description

In this activity, a panel of experts discuss current guidelines and best practices for the management of nontuberculous mycobacterial lung disease (NTM-LD), including treatment options for refractory disease and strategies for minimizing adverse effects of therapies. An experienced patient with NTM-LD shares her experiences with oral and inhaled therapies and how she overcame treatment challenges.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

1.00 CME
Global Education Group
A Breath of Fresh Air in Pediatric Asthma: Shared Decision-making in the Era of Biologics

A Breath of Fresh Air in Pediatric Asthma: Shared Decision-making in the Era of Biologics

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 3, 2021
Expires: August 3, 2022
60 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with pediatric asthma.

Statement of Need

Currently, more than 5.5 million children (age <18 years) in the United States have been diagnosed with asthma.1 An estimated 5% of this pediatric population suffer from severe asthma—disease that necessitates treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or oral corticosteroids (OCS) to retain control, or which remains uncontrolled despite this therapy.2,3 These children are at a heightened risk of death from recurrent, life-threatening asthma exacerbations, increased morbidity, impaired lung function, and reduced health-related quality of life.4-7 Asthma is the leading cause of emergency department visits and among the top 3 reasons children are hospitalized.8 Therefore, there is great urgency not only to prevent the detrimental effects of asthma but to implement timely and effective treatment plans for the management of these young patients.

During this Engaging the Patient™ program, two asthma specialists will share their interpretive insights on the characteristics of pediatric asthma, its underlying pathophysiology, and the rationale for targeted biologic therapies. Faculty will share clinical trial evidence for the use of newer biologic therapies within this pediatric population and detail the positioning of biologics within recently published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision-making will be included throughout the program, supporting the translation of information to practice. Lastly, prerecorded video vignettes of a parent’s testimonial and follow-up office visit will provide real-life perspectives on the immense burden of disease and the impact asthma has on patients and their families.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed April 14, 2021.
  2. Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
  3. Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
  4. Moorman JE, et al.Vital Health Stat 3. 2012(35):1-58.
  5. Sullivan SD, et al. Allergy. 2007;62(2):126-133.
  6. Strine TW, et al. Chest. 2004;126(6):1849-1854.
  7. Müllerová H, et al. J Asthma. 2020;1-12.
  8. American Lung Association. www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/asthma-children-facts-sheet#:~:text=In%202016%2C%203%2C651%20deaths%20were,adults%20over%2085%20years%20old. Accessed April 14, 2021.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Discuss pathophysiologic inflammatory processes in pediatric asthma that support phenotypic classification, risk stratification, and targeted treatment
  2. Longitudinally evaluate pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
  3. Describe the clinical profiles and evidence for current and emerging biologic treatment options for pediatric asthma
  4. Construct individualized treatment regimens for pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

Faculty

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical and Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas Medical Center
Kansas City, Kansas


Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children’s Hospital
Boston, Massachusetts

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the post-test and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mario Castro, MD, MPH
Consultant: Genentech, Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceuticals USA, Inc.;
Contracted Research: AstraZeneca, GlaxoSmithKline plc, Novartis International AG, Pulmatrix, Inc., Sanofi S.A., Shionogi Inc.;
Honoraria: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.;
Speakers Bureau: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.

Wanda Phipatanakul, MD, MS
Consultant: Genentech, Inc., GlaxoSmithKline plc, Novartis International AG, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: August 3, 2021
Expires: August 3, 2022
60 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with pediatric asthma.

Statement of Need

Currently, more than 5.5 million children (age <18 years) in the United States have been diagnosed with asthma.1 An estimated 5% of this pediatric population suffer from severe asthma—disease that necessitates treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or oral corticosteroids (OCS) to retain control, or which remains uncontrolled despite this therapy.2,3 These children are at a heightened risk of death from recurrent, life-threatening asthma exacerbations, increased morbidity, impaired lung function, and reduced health-related quality of life.4-7 Asthma is the leading cause of emergency department visits and among the top 3 reasons children are hospitalized.8 Therefore, there is great urgency not only to prevent the detrimental effects of asthma but to implement timely and effective treatment plans for the management of these young patients.

During this Engaging the Patient™ program, two asthma specialists will share their interpretive insights on the characteristics of pediatric asthma, its underlying pathophysiology, and the rationale for targeted biologic therapies. Faculty will share clinical trial evidence for the use of newer biologic therapies within this pediatric population and detail the positioning of biologics within recently published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision-making will be included throughout the program, supporting the translation of information to practice. Lastly, prerecorded video vignettes of a parent’s testimonial and follow-up office visit will provide real-life perspectives on the immense burden of disease and the impact asthma has on patients and their families.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed April 14, 2021.
  2. Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
  3. Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
  4. Moorman JE, et al.Vital Health Stat 3. 2012(35):1-58.
  5. Sullivan SD, et al. Allergy. 2007;62(2):126-133.
  6. Strine TW, et al. Chest. 2004;126(6):1849-1854.
  7. Müllerová H, et al. J Asthma. 2020;1-12.
  8. American Lung Association. www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/learn-about-asthma/asthma-children-facts-sheet#:~:text=In%202016%2C%203%2C651%20deaths%20were,adults%20over%2085%20years%20old. Accessed April 14, 2021.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Discuss pathophysiologic inflammatory processes in pediatric asthma that support phenotypic classification, risk stratification, and targeted treatment
  2. Longitudinally evaluate pediatric patients with asthma for disease severity, symptom control, lung function, and disease phenotypes
  3. Describe the clinical profiles and evidence for current and emerging biologic treatment options for pediatric asthma
  4. Construct individualized treatment regimens for pediatric patients with moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

Faculty

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical and Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas Medical Center
Kansas City, Kansas


Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Clinical Research Center
Division of Asthma, Allergy, Dermatology, Rheumatology, and Immunology
Boston Children’s Hospital
Boston, Massachusetts

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the post-test and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mario Castro, MD, MPH
Consultant: Genentech, Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceuticals USA, Inc.;
Contracted Research: AstraZeneca, GlaxoSmithKline plc, Novartis International AG, Pulmatrix, Inc., Sanofi S.A., Shionogi Inc.;
Honoraria: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.;
Speakers Bureau: AstraZeneca, Genentech, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Teva Pharmaceuticals USA, Inc.

Wanda Phipatanakul, MD, MS
Consultant: Genentech, Inc., GlaxoSmithKline plc, Novartis International AG, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / MOC
RMEI Medical Education, LLC
A Guide to Expediting the Recognition & Diagnosis of NTM-LD

A Guide to Expediting the Recognition & Diagnosis of NTM-LD

Start
Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: July 28, 2021
Expires: July 27, 2022
15 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the factors that place patients at risk for developing nontuberculous mycobacterial lung disease (NTM-LD)
  • Use current guidelines to facilitate NTM-LD diagnosis

Activity Description

This learner-friendly, 15-minute infographic activity is augmented by expert and patient videos with an interactive approach to recognizing risk factors for nontuberculous mycobacterial lung disease (NTM-LD) and using guidelines to facilitate a timely diagnosis.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: July 28, 2021
Expires: July 27, 2022
15 minutes to complete

Provided By

Provided by RMEI Medical Education, LLC.

Target Audience

This activity is intended for pulmonology, infectious disease, internal medicine clinicians, and other healthcare professionals involved in the treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the factors that place patients at risk for developing nontuberculous mycobacterial lung disease (NTM-LD)
  • Use current guidelines to facilitate NTM-LD diagnosis

Activity Description

This learner-friendly, 15-minute infographic activity is augmented by expert and patient videos with an interactive approach to recognizing risk factors for nontuberculous mycobacterial lung disease (NTM-LD) and using guidelines to facilitate a timely diagnosis.

Chair

Patrick A. Flume, MD
Professor, Medicine and Pediatrics
Medical University of South Carolina
Charleston, SC

Faculty

Doreen J. Addrizzo-Harris, MD
Professor of Medicine
Associate Director, Clinical and Academic Affairs
Director, NYU Bronchiectasis/NTM Program
NYU Grossman School of Medicine
New York, NY


Julie V. Philley, MD
Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Patrick A. Flume, MD, has financial relationships with AbbVie, Armata, AstraZeneca, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Insmed, Janssen, Merck, National Institutes of Health, Novartis, Novoteris, Novovax, Proteostasis Therapeutics, Savara, Sound Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc. (Grant/Research Support); Arrevus, Chiesi, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Hill-Rom, Insmed, Ionis Pharmaceuticals, Janssen Research & Development, McKesson, Merck, Novartis, Polyphor, Proteostasis Therapeutics, Santhera, Savara, Vertex Pharmaceuticals, Inc. (Consultant).

Doreen J. Addrizzo-Harris, MD, has no financial relationships to disclose.

Julie V. Philley, MD, has financial relationships with Insmed (Speaker's Bureau); A2N, Electromed, Insmed, Paratek (Consultant); A2N, Electromed, Hillrom, Insmed, Paratek, RedHill, Zambon (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC point(s), users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.50 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 4: Shared Decision-making in the Management of Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 4: Shared Decision-making in the Management of Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: July 28, 2021
Expires: July 28, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al.Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses
  • Describe how to promote shared decision making with patients with moderate-to-severe asthma and caregivers using disease state education and open communication about treatment options

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 67% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: July 28, 2021
Expires: July 28, 2022
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al.Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses
  • Describe how to promote shared decision making with patients with moderate-to-severe asthma and caregivers using disease state education and open communication about treatment options

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 67% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 3: A Case-Based Look at Managing Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 3: A Case-Based Look at Managing Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 13, 2021
Expires: July 13, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 13, 2021
Expires: July 13, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pages